We are pleased to announce that we have reached an agreement to partner with Charterhouse Capital Partners in the voluntary tender offer on all the ordinary shares issued by LABOMAR S.P.A., promoted by its founder Mr. Walter Bertin.

Headquartered in Treviso, LABOMAR is a full-service B2B innovation-driven CDMO, producing a wide range of nutraceutical products, medical devices and medical food supplements, with 2022 sales of €92m and EBITDA of €17m.

We have backed LABOMAR since its IPO on the Italian stock exchange Euronext Growth Milan in October 2020 and we wish to continue to support the company alongside Charterhouse Capital Partners, one of the longest-established private equity firms operating in Europe, with prior investment experience in Italy and expertise in the healthcare sector.

For an exhaustive and detailed description of the terms and conditions of the offer, please refer to the notice pursuant to Article 102 of the Italian Financial Act published on LABOMAR website.

 

[Read the news]